tbuckley/cabot-search huggingface dataset:
Poverty and Response to Treatment Among Panic Disorder Patients in Primary Care
Authors: Peter Roy-Byrne
Journal: American Journal of Psychiatry (2006)

Objective: Despite well-established links between poverty and poor mental illness outcome as well as recent reports exploring racial and ethnic health disparities, little is known about the outcomes of evidence-based psychiatric treatment for poor individuals. Method: Primary care patients with panic disorder (N=232) who were participating in a randomized controlled trial comparing a cognitive behavior therapy (CBT) and pharmacotherapy intervention to usual care were divided into those patients above (N=152) and below (N=80) the poverty line. Telephone assessments at 3, 6, 9, and 12 months were used to compare the amount of evidence-based care received as well as clinical and functional outcomes. Results: Poor subjects were more severely ill at baseline, with more medical and psychiatric comorbidity. The increases in the amount of evidence-based care and reductions in clinical symptoms and disability were comparable in the two groups such that poorer individuals, although responding equivalently, continued to be more ill and disabled at 12 months. Conclusions: The comparable response of poor individuals in this study suggests that standard CBT and pharmacotherapy treatments for panic disorder do not need to be “tailored” to be effective in poor populations. However, the more severe illness both at baseline and follow-up in these poor individuals suggests that treatment programs may need to be extended in order to treat residual symptoms and disability in these patients so that they might achieve comparable levels of remission.
KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
Authors: D. Rodriguez Abreu, M.C. Garassino, E. Esteban, G. Speranza, E. Felip, M. Domine, M.J. Hochmair, S. Powell, S.Y.-S. Cheng, H.G. Bischoff, N. Peled, R. Hui, M. Reck, E.B. Garon, M. Boyer, F. Grossi, R. Jennens, J. Yang, M.C. Pietanza, S. Gadgeel
Journal: Annals of Oncology (2018)
Error in In-Text Citations
Authors: Karlo Lizarraga, Philip Thompson, Anthony Lang, Edmond Safra, Gloria Shulman
Journal: JAMA Neurology (2019)

Anne Bertrand, MD, PhD; Junhao Wen, MS; Daisy Rinaldi, PhD; Marion Houot, MS; Sabrina Sayah, MS; Agnès Camuzat, PhD; Clémence Fournier, PhD; Sabrina Fontanella, MS; Alexandre Routier, MS; Philippe Couratier, MD; Florence Pasquier, MD, PhD; Marie-Odile Habert, MD; Didier Hannequin, MD, PhD; Olivier Martinaud, MD, PhD; Paola Caroppo, MD, PhD; Richard Levy, MD, PhD; Bruno Dubois, MD; Alexis Brice, MD; Stanley Durrleman, PhD; Olivier Colliot, PhD; Isabelle Le Ber, MD, PhD; for the Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (PREV-DEMALS) Study Group
Corticosteroids for Patients With Septic Shock
Authors: Babak Mokhlesi
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ASK1-dependent recruitment and activation of macrophages induce hair growth in skin wounds
Authors: Nao Osaka, Takumi Takahashi, Shiori Murakami, Atsushi Matsuzawa, Takuya Noguchi, Takeshi Fujiwara, Hiroyuki Aburatani, Keiji Moriyama, Kohsuke Takeda, Hidenori Ichijo
Journal: The Journal of Experimental Medicine (2007)
Use of Polishing Machines in Hospitals
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A clinical experience with an implanted mechanical auxiliary ventricle
Authors: A. Kantrowitz
Journal: JAMA (1966)

A mechanical auxiliary ventricle for intermittent permanent assistance was implanted Feb 4, 1966, in a 33year-old man with intractable left ventricular failure due to idiopathic cardiomyopathy. When the ventricle began functioning, systemic pressure was returned to normal as was left auricular pressure. During the immediate postoperative period the patient maintained fair stability with arterial pressure remaining at physiologic levels. The patient's sensorium appeared normal postoperatively. His activity required sedation. No unusual sensations related to the implantation were reported. Despite a good clinical picture, a constantly increasing pulse rate rose to 160 to 180 beats per minute. Eleven hours postoperatively his left auricular and central venous pressure rose sharply while peripheral arterial pressure fell. The patient died 20 hours and 30 minutes following completion of the operation. Cause of death is not fully understood but may be related to prolonged uncontrollable tachycardia.
Malaria transmission by platelet concentrate transfusion
Authors: M. D. Garfield
Journal: JAMA (1978)

MALARIA is a well-recognized complication of transfusion therapy that is being encountered with increasing frequency in nonmalarious areas of the world.<sup>1</sup>Most cases have derived from administration of infected whole blood or packed RBCs,<sup>1-3</sup>but reports have also implicated leukocyte concentrates<sup>4</sup>and even fresh plasma.<sup>5-7</sup>Platelet concentrates have been ascribed as the source of one case of transfusion malaria<sup>8</sup>; however, neither confirmatory data nor clinical details were provided. We report a well-documented case of<i>Plasmodium falciparum</i>malaria transmitted by platelet concentrate transfusion. <h3>Report of a Case</h3> A 57-year-old woman with acute myelomonocytic leukemia was readmitted to the hospital on June 27, 1977, in leukemic relapse. Between December 1976 and June 1977, she had received no blood products and she had never traveled outside the United States. Physical findings were unremarkable except for pallor, and she was afebrile. The hematocrit level was 32%; the WBC count, 7,100/cu
Critical involvement of interferon ? in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis
Authors: H Mizuhara, M Uno, N Seki, M Yamashita, M Yamaoka, T Ogawa, K Kaneda, T Fujii, H Senoh, H Fujiwara
Journal: Hepatology (1996)

A single intravenous injection of concanavalin A (Con A) induces T–cell activation and an acute hepatitis in mice. This study investigated the role of interferon γ (IFN–γ) in the pathogenesis of this hepatitis model. Striking increases in the plasma levels of various cytokines, including tumor necrosis factor (TNF), interleukin–2 (IL–2), and IFN–γ, were detected before the increase in plasma aminotransferase levels induced by Con A injection. TNF levels peaked within 2 hours, whereas IFN–γ levels peaked at 6 hours after Con A injection. In contrast to a sharp peak of TNF levels, high IFN–γ levels were detected for a more prolonged period. Passive immunization with anti–IFN–γ monoclonal antibody (MAb) conferred a dose–dependent protection against liver injury in this model. This protection was observed when anti–IFN–γ MAb was administered at least 30 minutes before Con A injection but not when given 1 hour after Con A injection. The protection from Con A–induced hepatitis was also induced by administration of rIL–6 before Con A injection. rIL–6 treatment induced significant albeit incomplete inhibition of IFN–γ and TNF production, whereas this regimen did not affect IL–2 production. Despite striking protective effects of rIL–6 or anti–IFN–γ MAb, comparable levels of cellular (both T cell and polymorphonuclear cell) infiltration were detected in liver sections from animals untreated, or treated with either rIL–6 or anti–IFN–γ MAb. Moreover, electron microscopic examination showed that infiltrating T cells exhibited a blastoid appearance in all groups. These results indicate that IFN–γ plays a critical role in the development of Con A–induced acute hepatitis and suggest that IL–6 administration can regulate the manifestation of hepatitis through mechanisms including the reduced production of inflammatory cytokines such as IFN–γ.
Maimonides
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Polybrominated Biphenyl Toxicosis in Rats Fed an Iodine-Deficient, Iodine-Adequate, or Iodine-Excess Diet
Authors: S. D. Sleight, Soesanto Mangkoewidjojo, B. T. Akoso, V. L. Sanger
Journal: Environmental Health Perspectives (1978)

Young male Sprague-Dawley rats were fed 0, 1, 10, or 100 ppm of polybrominated biphenyls (PBB) in iodine-deficient, iodine-adequate (0.2 ppm), or iodine-excess (1000 ppm) diets. Six rats in each of the 12 groups were killed at 30 days and the remaining six in each group at 60 days. Growth rates were similar in all rats fed diets containing 0, 1, or 10 ppm PBB but were slower from 30 to 60 days in rats given 100 ppm PBB. Results of routine hematologic examinations and urinalyses were essentially normal. Although liver weights were substantially increased by PBB, the smallest increases were in rats fed an iodine-deficient diet. Thyroid weights were increased by iodine deficiency and by 10 and 100 ppm PBB. Electropherograms of serum proteins, serum lipoproteins, and LDH isozymes at 60 days from rats given PBB indicated hepatic alterations, but changes were least dramatic in rats fed an iodine-deficient diet plus PBB and most severe in rats fed iodine-excess diets plus PBB. Hepatic lesions were basically similar to those previously described except that bile duct proliferation was seen at 60 days only in rats fed an iodine-deficient diet and 100 ppm PBB. Histologic changes in thyroid glands were associated with iodine deficiency and with PBB. The iodine-excess diet plus 100 ppm PBB induced squamous metaplasia of respiratory bronchiolar epithelium. These results indicate interrelationships between PBB and iodine which may affect the toxicosis caused by PBB.
PALESTINE
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Massachusetts Medical Society
Authors: Merritt B. Low
Journal: New England Journal of Medicine (1975)

LAWRENCE R. DAME, M.D.Lawrence Raymond Dame died in August, 1974, while on a camping trip with his family in Wisconsin, a victim of (as far as is known) his first coronary attack. Thus ended a long and productive career in medicine and community life. Dr. Dame's great zeal, accuracy, and conscientiousness showed most clearly through his collection of carefully investigated, documented, and recorded collections of historical memorabilia in the medical field. His commitment to the community showed in his participation in countless committees of hospital staffs, mental health, and physician liaison groups. He usually ended up as chairman. Woe . . .
BCG vaccination and leukemia mortality
Authors: S. R. Rosenthal
Journal: JAMA (1972)

In Chicago from 1964 through 1969, one death from leukemia was recorded among 54,414 infants 0 through 6 years of age, who were vaccinated at birth with BCG vaccine, a rate of 0.31/100,000/yr. In contrast, among 172,986 infants of a similar age and race who were not vaccinated, 21 deaths were reported, a rate of 2.02/100,000/ yr. The difference is statistically significant (P =.04) and suggests the value of BCG vaccinations in preventing leukemia in children, but since this is a retrospective study, no firm conclusions can be drawn.
Desert Storm: medical airlift was ready
Authors: A. Skolnick
Journal: JAMA (1991)

IN PEACETIME, the US military's aeromedical evacuation system transports 250 to 300 patients a day to facilities where they can receive specialized care. Anticipating heavy casualties from fighting in the Persian Gulf, the Air Force instituted contingency plans for expanding this system to "comfortably" move up to 1500 patients a day. However, in one of the happiest outcomes of the Desert Storm operation, the total of allied wounded is much lower than commanders feared. So the Military Airlift Command (MAC) was not called on to demonstrate the aeromedical evacuation system's maximum capability. <h3>Practicing for War</h3> One of the missions of MAC, which is headquartered at Scott Air Force Base (AFB) in southern Illinois, is to transport war casualties from medical facilities in or close to the theater of military operations to hospitals in neighboring countries or the United States where the casualties can receive more definitive care. It stays prepared
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Authors: Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott, Frederick J. Raal, Dirk J. Blom, Jennifer Robinson, Christie M. Ballantyne, Ransi Somaratne, Jason Legg, Scott M. Wasserman, Robert Scott, Michael J. Koren, Evan A. Stein
Journal: New England Journal of Medicine (2015)

Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies. We conducted two extension studies to obtain longer-term data.In two open-label, randomized trials, we enrolled 4465 patients who had completed 1 of 12 phase 2 or 3 studies ("parent trials") of evolocumab. Regardless of study-group assignments in the parent trials, eligible patients were randomly assigned in a 2:1 ratio to receive either evolocumab (140 mg every 2 weeks or 420 mg monthly) plus standard therapy or standard therapy alone. Patients were followed for a median of 11.1 months with assessment of lipid levels, safety, and (as a prespecified exploratory analysis) adjudicated cardiovascular events including death, myocardial infarction, unstable angina, coronary revascularization, stroke, transient ischemic attack, and heart failure. Data from the two trials were combined.As compared with standard therapy alone, evolocumab reduced the level of LDL cholesterol by 61%, from a median of 120 mg per deciliter to 48 mg per deciliter (P<0.001). Most adverse events occurred with similar frequency in the two groups, although neurocognitive events were reported more frequently in the evolocumab group. The risk of adverse events, including neurocognitive events, did not vary significantly according to the achieved level of LDL cholesterol. The rate of cardiovascular events at 1 year was reduced from 2.18% in the standard-therapy group to 0.95% in the evolocumab group (hazard ratio in the evolocumab group, 0.47; 95% confidence interval, 0.28 to 0.78; P=0.003).During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels and reduced the incidence of cardiovascular events in a prespecified but exploratory analysis. (Funded by Amgen; OSLER-1 and OSLER-2 ClinicalTrials.gov numbers, NCT01439880 and NCT01854918.).
Serum 2,3,7,8-Tetrachlorodibenzo-p-dioxin Levels in Air Force Health Study Participants—Preliminary Report
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Radiologic Evaluation of Heart Size in Rheumatic Heart Disease
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GLUTATHIONE TRANSFERASES
Authors: John D. Hayes, Jack U. Flanagan, Ian R. Jowsey
Journal: The Annual Review of Pharmacology and Toxicology (2004)

This review describes the three mammalian glutathione transferase (GST) families, namely cytosolic, mitochondrial, and microsomal GST, the latter now designated MAPEG. Besides detoxifying electrophilic xenobiotics, such as chemical carcinogens, environmental pollutants, and antitumor agents, these transferases inactivate endogenous alpha,beta-unsaturated aldehydes, quinones, epoxides, and hydroperoxides formed as secondary metabolites during oxidative stress. These enzymes are also intimately involved in the biosynthesis of leukotrienes, prostaglandins, testosterone, and progesterone, as well as the degradation of tyrosine. Among their substrates, GSTs conjugate the signaling molecules 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2) and 4-hydroxynonenal with glutathione, and consequently they antagonize expression of genes trans-activated by the peroxisome proliferator-activated receptor gamma (PPARgamma) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2). Through metabolism of 15d-PGJ2, GST may enhance gene expression driven by nuclear factor-kappaB (NF-kappaB). Cytosolic human GST exhibit genetic polymorphisms and this variation can increase susceptibility to carcinogenesis and inflammatory disease. Polymorphisms in human MAPEG are associated with alterations in lung function and increased risk of myocardial infarction and stroke. Targeted disruption of murine genes has demonstrated that cytosolic GST isoenzymes are broadly cytoprotective, whereas MAPEG proteins have proinflammatory activities. Furthermore, knockout of mouse GSTA4 and GSTZ1 leads to overexpression of transferases in the Alpha, Mu, and Pi classes, an observation suggesting they are part of an adaptive mechanism that responds to endogenous chemical cues such as 4-hydroxynonenal and tyrosine degradation products. Consistent with this hypothesis, the promoters of cytosolic GST and MAPEG genes contain antioxidant response elements through which they are transcriptionally activated during exposure to Michael reaction acceptors and oxidative stress.